TrialSignal
Clinical trial intelligence report
A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03136809
Status
UNKNOWN
Phase
PHASE1
Sponsor
Collaborative Medicinal Development Pty Limited
Executive brief
Investment-Ready Snapshot
Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03136809
Indication
Amyotrophic Lateral Sclerosis
Modality
small molecule
Target
Cu(II)ATSM
Intervention
Cu(II)ATSM
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.